Recombinant Human IL-13 Protein, CF

Name: Recombinant Human IL-13 Protein, CF
Brand: R&D Systems
SKU: 213-ILB/CF
Price: 6862 USD
Availability: InStock

R&D Systems | Catalog # 213-ILB/CF

Submit a review

Citations (132)

Product Documents

View Available Conjugates

100% Guarantee

Product Specifications
Scientific Data
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Source

E. coli

Accession Number

AAK53823

Applications

Bioactivity

View all IL-13 Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human IL-13 protein
Gly21-Asn132

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Gly21

Predicted Molecular Mass

12.3 kDa

SDS-PAGE

9 kDa, reducing conditions

Activity

Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323.
The ED₅₀ for this effect is 0.5-2.5 ng/mL.

Scientific Data Images for Recombinant Human IL-13 Protein, CF

Bioactivity of Human IL-13 Protein

Recombinant human IL-13 (213-ILB/CF) stimulates proliferation in the TF-1 human erythroleukemic cell line. The ED₅₀ for this effect is 0.5-2.5 ng/mL.

Formulation, Preparation, and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 213-ILB/CF

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in PBS.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Carrier Free: 213-ILB

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution	Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: IL-13

Interleukin-13 (IL-13) is a monomeric 17 kDa immunoregulatory cytokine that plays a key role in the pathogenesis of allergy, cancer, and tissue fibrosis. It is secreted by several helper T cell subsets, NK cells, mast cells, eosinophils, basophils, and visceral smooth muscle cells (1‑3). Mature human IL-13 shares approximately 58% amino acid sequence identity with mouse and rat IL-13. Despite the low homology, it exhibits cross‑species activity between human, mouse, and rat (4). IL-13 suppresses the production of proinflammatory cytokines and other cytotoxic substances by macrophages, fibroblasts, and endothelial cells. On B cells, it promotes cellular activation, immunoglobulin class switching to IgE, and the up‑regulation of CD23/Fc epsilon RII (1, 5). IL-13 binds with low affinity to the transmembrane IL-13 R alpha 1 which then forms a signaling complex with the transmembrane IL-4 R alpha (6‑8). This high affinity receptor complex also functions as the type 2 IL-4 receptor (6, 7). IL‑13 R alpha 2 inhibits responses to both IL-13 and IL-4. It binds IL-13 with high affinity (9, 10) and prevents IL-13 from signaling through the IL-13 R alpha 1/IL-4 R alpha complex (11, 12). It also blocks signaling through IL-4-occupied IL-13 R alpha 1/IL-4 R alpha receptor complexes (12, 13). In addition, IL-13-bound IL-13 R alpha 2 can directly promote tumor cell invasiveness and the development of tissue fibrosis (14‑16).